Brought to you by 
Merus acquires North American rights to Cornerstone's Factive and Spectracef
23 Sep 2020
Executive Summary
In a move to exit the primary care market and focus on selling hospital-based drugs, Cornerstone Therapeutics Inc. (a specialty drug division owned 51% by Chiesi Farmaceutici SPA) has sold Merus Labs International Inc. North American rights to two antibiotics--Factive (gemifloxacin mesylate) 320mg tablets and Spectracef (cefditoren pivoxil). Specific financial terms were not disclosed but Merus paid total consideration up-front as a multiple of product cash flow.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merus acquires North American rights to Cornerstone's Factive and Spectracef
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice